Progression of myelodysplasia patient 1
Time from Primary Diagnosis . | Karyotype . | FISH Results . | Clinical Status . | TP53 Status . |
---|---|---|---|---|
0 mo | 46, XX, t(15;17)(q22;q21) | APL t(15;17) | Presentation | Normal |
6 mo | 46, XX | Complete Remission | Normal | |
21 mo | ND | 13% der(5;17) | Complete Remission | Normal |
24 mo | ND | 33% der(5;17) | Complete Remission | Normal |
29 mo | 45, XX, −5, add(17)(p11.2)[6] | 43% der(5;17) | Complete Remission | Normal |
32 mo | 45, XX, −5, add(17)(p11.2)[19] | 74% der(5;17) | Complete Remission | Normal/Mutant |
35 mo | 45, XX, −5, add(17)(p11.2)[5] 42-45, XX, chromosomes exhibiting shared abnormalities consisting of −3, −5, add(6)(p25), −7, −14, −15, add(17)(p11.2), +2mar[15] | 95% der(5;17) | Relapse MDS 9% blasts | Mutant |
Time from Primary Diagnosis . | Karyotype . | FISH Results . | Clinical Status . | TP53 Status . |
---|---|---|---|---|
0 mo | 46, XX, t(15;17)(q22;q21) | APL t(15;17) | Presentation | Normal |
6 mo | 46, XX | Complete Remission | Normal | |
21 mo | ND | 13% der(5;17) | Complete Remission | Normal |
24 mo | ND | 33% der(5;17) | Complete Remission | Normal |
29 mo | 45, XX, −5, add(17)(p11.2)[6] | 43% der(5;17) | Complete Remission | Normal |
32 mo | 45, XX, −5, add(17)(p11.2)[19] | 74% der(5;17) | Complete Remission | Normal/Mutant |
35 mo | 45, XX, −5, add(17)(p11.2)[5] 42-45, XX, chromosomes exhibiting shared abnormalities consisting of −3, −5, add(6)(p25), −7, −14, −15, add(17)(p11.2), +2mar[15] | 95% der(5;17) | Relapse MDS 9% blasts | Mutant |
ND = not done; APL = acute promyelocytic leukemia; MDS = myelodysplasia.